Corpus Intelligence IC Memo — WOODLAND HEALTHCARE 2026-04-26 12:37 UTC
IC Memo — WOODLAND HEALTHCARE
Investment Committee Memorandum | CA | 74 beds | Grade C | EBITDA uplift $15.6M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

WOODLAND HEALTHCARE

CCN 050127 | YOLO, CA | 74 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

WOODLAND HEALTHCARE is a 74-bed suburban community hospital in YOLO, CA with $211.5M in net patient revenue and a -3.2% operating margin. The hospital serves a payer mix of 26.4% Medicare, 3.3% Medicaid, and 70.3% commercial.

Thesis: Turnaround. Our ML models identify $15.6M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -3.2% to 4.2% (+736bps).

Net Revenue HCRIS$211.5M
Current EBITDA COMPUTED$-6.8M
Operating Margin COMPUTED-3.2%
Occupancy HCRIS41.5%
Revenue / Bed COMPUTED$2.9M
Net-to-Gross HCRIS23.3%
Distress Probability ML46.6%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
145
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of -3.2% places it above the state median. Among 145 size-comparable peers (37-148 beds), the median margin is -4.9%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (37-148), prioritizing same-state peers. 145 hospitals in the comp set.

HospitalStateBedsRevenueMargin
WOODLAND HEALTHCARE (Target)CA74$211.5M-3.2%
CONTRA COSTA REGIONAL MEDICAL CA124$595.0M-29.2%
RANCHO LOS AMIGOS NATL.REHAB.CCA83$512.6M41.9%
USC NORRIS CANCER HOSPITALCA60$468.7M19.1%
KFH - ANTIOCHCA144$445.4M8.1%
KFH - VACAVILLECA144$415.3M7.1%
EDEN MEDICAL CENTERCA126$389.8M2.7%
KFH - REDWOOD CITYCA140$379.7M-4.5%
SUTTER SANTA ROSA REGIONAL HOSCA124$374.4M-0.2%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $15.6M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$4.4M+210bp18mo
Cost to Collect4.5%2.5%$4.2M+200bp12mo
Denial Rate Reduction12.0%6.5%$4.2M+198bp12mo
A/R Days Reduction5200.0%3800.0%$2.6M+122bp9mo
Clean Claim Rate88.0%96.0%$135K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$4.4M
Cost to Collect
$4.2M
Denial Rate Reduction
$4.2M
A/R Days Reduction
$2.6M
Clean Claim Rate
$135K
Total EBITDA Uplift$15.6M
Current EBITDA$-6.8M
+ RCM Uplift+$15.6M
Pro Forma EBITDA$8.8M
Current Margin-3.2%
Pro Forma Margin4.2%
WC Released (1x)$8.1M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-10.4M$111.0M0.00x-100.0%
Base (11x exit)10.0x11.0x$-10.4M$118.7M0.00x-100.0%
Bull Case9.0x11.0x$-9.4M$166.7M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-9.4M$179.0M0.00x-100.0%
Bear Case11.0x10.0x$-11.5M$36.5M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-11.5M$36.4M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 145 hospitals with 37-148 beds
  • Same-state prioritization (n=146)
  • Comp margins: P25=-21.6% / P50=-4.9% / P75=3.5%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.